新型表达载体 pEC34 试用于人 γ 干扰素基因的高表达

构建了一个新的双顺反子表达载体ｐＥＣ３４,它的第一个顺反子是已高表达的ｅｒａ基因的部分序列,并带有原核翻译增强子。当检测ｐＥＣ３４的可用性时,获得了人γ－干扰素的极高表达。目的蛋白占菌体总蛋白的８５．５％,诱导后经ＳＤＳ－ＰＡＧＥ分析,出现分子量为１５．５ｋＤａ左右的蛋白表达带。Ｗｅｓｔｅｒｎ ｂｌｏｔ结果证实为人γ－干扰素。无压力传代３０次表达质粒仍然稳定,表明ｐＥＣ３４可能用作真核蛋白质高表达     

人微小纤溶酶基因的克隆和表达

用ＰＣＲ方法扩增人微小纤溶酶原（Ｍｉｃｒｏｐｌａｓｍｉｎｇｅｎ,ｍＰｌｇ）基因,再与表达戴本重组,构造ｍＰｌｇ原核表达质粒并转化大肠杆菌,阳性克隆ｐＳＳＥ－ｍＰｌｇ经温度诱导表达,ＳＤＳ－ＰＡＧＥ等方法证明表达产物的分子量约为２９ｋＤａ占全菌总蛋白的２４％左右,并在菌内形成包涵体,经半胱氨酸再氧化法和空气氧化法复法,表达产物的ｒ－ｍＰｌｇ经ＳＫ作用后显示纤溶活性。同时对蛋白质浓度,复性时间等因素对     

DC-SIGN胞外区基因的克隆、蛋白表达及抗体制备

旨在构建DC-SIGN胞外区基因原核表达质粒,诱导蛋白表达并制备多克隆抗体。用PCR的方法扩增编码DC-SIGN胞外区的基因序列,将其克隆到原核表达载体pET-28a(+)中,利用大肠杆菌表达系统表达DC-SIGN胞外区蛋白,用H is抗体做W estern Blotting鉴定目的蛋白的免疫原性。用纯化的DC-SIGN胞外区蛋白免疫日本大耳白兔,制备多克隆抗体。通过酶联免疫吸附试验(ELISA)检测抗体效价,免疫荧光法检测其特异性。结果显示,原核表达载体pET-28 a(+)-DC-SIGN胞外区基因成功构建,可在大肠杆菌BL21(DE3)中高效表达,获得相对分子质量约20 kD的DC-SIGN胞外区蛋白,经Westernb lotting鉴定为正确。纯化后的蛋白免疫大耳白兔,制备的多克隆抗体具有较强免疫原性和特异性。本研究得到了纯化的DC-SIGN胞外区蛋白,并制备了具有特异性和高效价的抗体,为研究DC-SIGN生物学功能提供试验基础。     

人vasorin蛋白的基因克隆、表达及纯化简

目的：克隆、表达人vasorin（VASN）蛋白。方法：利用PCR方法从HepG2细胞的cDNA中扩增获得目的基因,并插入带有6xHis标签的原核高效可溶性表达载体pET28a中,构建重组表达质粒pET28a-VASN,将重组表达质粒转化大肠杆菌BL21（DE3）,经IPTG诱导后目的基因获得表达,对融合目的蛋白进行Ni^2＋金属螯合柱纯化。结果：内切酶鉴定及基因序列测定证实重组表达质粒构建成功;对目的蛋白进行了原核表达,SDS-PAGE显示相对分子质量为61x10^3的特异表达条带;Western印迹证实目的蛋白为VASN,且主要以包涵体形式存在;对经尿素变性的表达产物进行了亲和层析纯化,有利于以后的变性、复性过程。结论：获得了人VASN融合蛋白,为其进一步的生物学功能研究奠定了基础。     

人vasorin蛋白的基因克隆、表达及纯化

目的:克隆、表达人vasorin(VASN)蛋白。方法:利用PCR方法从HepG2细胞的cDNA中扩增获得目的基因,并插入带有6×His标签的原核高效可溶性表达载体pET28a中,构建重组表达质粒pET28a-VASN,将重组表达质粒转化大肠杆菌BL21(DE3),经IPTG诱导后目的基因获得表达,对融合目的蛋白进行Ni2+金属螯合柱纯化。结果:内切酶鉴定及基因序列测定证实重组表达质粒构建成功;对目的蛋白进行了原核表达,SDS-PAGE显示相对分子质量为61×103的特异表达条带;Western印迹证实目的蛋白为VASN,且主要以包涵体形式存在;对经尿素变性的表达产物进行了亲和层析纯化,有利于以后的变性、复性过程。结论:获得了人VASN融合蛋白,为其进一步的生物学功能研究奠定了基础。     

利用GST融合蛋白表达系统表达与纯化人N-Ras蛋白

目的:克隆人N-ras蛋白全长编码区基因,获得其原核表达产物,并对融合蛋白进行纯化。方法:采用PCR技术从人乳腺文库中扩增出人N-ras蛋白全长编码区基因,将其克隆到p GEX-KG载体中,在大肠杆菌Rossate中表达后,利用GST-Sepharose 4B亲和珠对原核表达产物进行纯化,SDS-PAGE鉴定表达与纯化产物。结果:从人乳腺文库中扩增获得约600 bp的DNA片段,并克隆至p GEX-KG载体上,经测序与目的序列完全一致;在大肠杆菌Rossate中诱导表达出相对分子质量约47×103的目的蛋白;纯化后,经鉴定获得了纯度较高的重组蛋白GST-N-Ras。结论:获得了重组蛋白GST-N-ras,为后续深入研究Ras基因与其他癌基因、抑癌基因的相互作用奠定了基础。     

棉铃虫单核衣壳核多角体病毒几丁质酶基因的克隆与表达

根据棉铃虫单核衣壳核多角体病毒 (HaSNPV)几丁质酶基因的序列 ,设计引物 ,引入适当的酶切位点 ,利用PCR扩增出不含N末端信号肽以及C末端内质网定位肽的几丁质酶基因片段。将该基因片断克隆至原核表达载体 pProEXHTb ,经IPTG诱导 ,在大肠杆菌DH5α中获得了高效表达 ,表达产物的大小为 6 0kD ,含量占菌体总蛋白量的 4 0 %。利用来源于AcMNPV几丁质酶的抗体对表达蛋白进行检测 ,获得特异性的显色信号 ,证实所获原核表达产物与杆状病毒的几丁质酶具有同源性     

RGD肽与尿激酶B链融合蛋白原核重组表达质粒的构建,表达和？…

将化学合成的ＲＧＤ肽（Ａｒｇ－Ｇｌｙ－Ａｓｐ）编码寡核苷酸与尿激酶Ｂ链ｃＤＮＡ相连成为融合基因后,克隆至原核表达质粒ｐＢＶ２２０中,在ＰＲＰＬ自动子的作用下,经４２℃热诱导,在大肠杆菌ＤＨ５α中获得了融合基因的表达,其表达量占菌体总蛋白的９．２％,表达产物以无活性的包含体形式存在。经变复性处理得到纯化的融合基因的表达产物,经Ｗｅｓｔｅｒｎ－ｂｌｏｔｔｉｎｇ分析表明产物具有与天然尿激酶相似的抗原性,     

棉铃虫单核衣壳核多角体病毒几丁质酶基因的克隆与表达

根据棉铃虫单核衣壳核多角体病毒(HaSNPV)几丁质酶基因的序列,设计引物,引入适当的酶切位点,利用PCR扩增出不含N末端信号肽以及C末端内质网定位肽的几丁质酶基因片段.将该基因片断克隆至原核表达载体pProEXHTb,经IPTG诱导,在大肠杆菌DH5α中获得了高效表达,表达产物的大小为60kD,含量占菌体总蛋白量的40%.利用来源于AcMNPV 几丁质酶的抗体对表达蛋白进行检测,获得特异性的显色信号,证实所获原核表达产物与杆状病毒的几丁质酶具有同源性.     

人乳头瘤病毒6型L1基因的克隆及蛋白表达

目的：在大肠杆菌中表达经密码子优化的人乳头瘤病毒6型（HPV6）L1的融合蛋白。方法：PCR方法扩增HPV6 L1,基因,测序及序列比对后,对基因进行密码子优化并合成优化后的基因HPV6mLI,将其克隆入原核表达载体pGEX4T-1,IPTG诱导融合蛋白在大肠杆菌BL21（DE3）中表达,SDS-PAGE鉴定表达产物。结果：酶切和测序结果证实HPV6 mL1基因的原核表达载体构建正确;以1mmol／L IPTG于37℃诱导4h,蛋白以包涵体形式表达;表达产物的相对分子质量与预期值一致,为80000。结论：获得大肠杆菌表达的HPV6L1蛋白,为其结构功能研究和疫苗研发提供了基础。     

Monkey erythropoietin gene: cloning, expression and comparison with the human erythropoietin gene

The erythropoietin (Epo) gene from Cynomolgus monkeys has been isolated from a kidney cDNA library using mixed 20-mer oligodeoxynucleotide probes. The gene encodes a 168 amino acid (aa) mature protein with a calculated Mr of 18,490 and a presumptive signal peptide of 24 aa. The Epo gene, when transfected into Chinese hamster ovary (CHO) cells, produces a glycosylated protein with an apparent Mr of 34,000. The expressed product is biologically active in vivo. The monkey gene exhibits 92% and 94% homology to the human gene at the aa and nucleotide sequence levels, respectively. When compared with the human Epo, monkey Epo has an additional 3-aa residue at the N terminus of the mature protein and a deletion of an internal lysine residue.     

Cloning and characterization of a proliferation-associated cytokine-inducible protein, CIP29

We identified a novel erythropoietin (Epo)-induced protein (CIP29) in lysates of human UT-7/Epo leukemia cells using two-dimensional gel analysis and cloned its full-length cDNA. CIP29 contains 210 amino acids with a predicted MW of 24 kDa, and has a N-terminal SAP DNA-binding motif. CIP29 expression was higher in cancer and fetal tissues than in normal adult tissues. CIP29 mRNA expression is cytokine regulated in hematopoietic cells, being up-regulated by Epo in UT7/Epo cells, and by thrombopoietin (Tpo), FLT3 ligand (FL) and stem cell factor (SCF) in primary human CD34(+) cells. Up-regulation of CIP29 in UT7/Epo cells by Epo was associated with cell cycle progression but not with antiapoptosis. Epo withdrawal reduced CIP29 expression concomitant with cell cycle arrest. Overexpression of CIP29-GFP in HEK293 cells enhances cell cycle progression. CIP29 appears to be a new cytokine regulated protein involved in normal and cancer cell proliferation.     

The prolonged half-lives of new erythropoietin derivatives via peptide addition

Erythropoietin, or Epo, is a hematopoietic cytokine that promotes erythropoiesis, and recombinant human Epo has been used in the treatment of anemia in various chronic diseases. Here, we have constructed novel Epo derivatives with prolonged half-lives by adding peptides to the carboxy terminus of Epo without using linkers. The fused peptides were selected from the carboxy terminal region of human chorionic gonadotropin (hCG) or human thrombopoietin (hTpo), which promote the proper folding, secretion, and stabilization of bioactive glycoproteins. Addition of these peptides did not interfere with secretion or receptor binding, and significantly increased the in vivo half-life of human Epo, as measured by intravenous administration in rats. The plasma half-life of the Epo constructs was longest when the carboxy terminal 28 aa of the beta subunit of hCG was added (Epo-CGC), a half-life that was slightly longer than NESP (Aranesp), which is the most effective Epo product in current clinical use. The transformation of four Ser glycosylation sites to Ala on the CGC sequence also lengthened the plasma half-life of Epo, indicating that the in vivo stabilizing effect of the hCG peptide was due to both structures within the peptide itself and its O-glycosylations. The application of the carboxy terminal half of hTpo also resulted in remarkably reduced elimination of the Epo chimera (Epo-TpC), possibly due to protection by the TpC sequence. The in vivo hematopoietic activity of Epo derivatives in mice was consistent with their pharmacokinetic profiles. Therefore, these derivatives with prolonged half-lives may provide opportunities for developing new Epo therapeutics with less frequent administration.     

人ob基因克隆及其亚细胞定位的研究

目的:旨在克隆人肥胖(obese,ob)基因的全长cDNA序列,与EGFP重组构建融合蛋白表达载体,并分析其亚细胞水平的定位.方法:提取人脂肪细胞总RNA,采用RT-PCR方法扩增出人ob基因cDNA,并克隆至真核表达载体pEGFP-CI,重组质粒转染NIH-3T3细胞,荧光显微镜分析EGFP-ob融合蛋白的亚细胞定位.结果:克隆的ob基因cDNA为501bp,共编码167个氨基酸,与GenBank公布的人ob基因序列一致,荧光显微镜分析表明,重组的EGFP-ob融合蛋白主要分布于NIT-3T3的细胞质中.结论:成功克隆了人OB基因的cDNA序列,构建人OB基因的真核表达载体pEGFP-CI-ob,融合蛋白EGFP-ob定位于NIH-3T3细胞质中.